All articles tagged with #wegovy pill
Novo Nordisk's Wegovy® pill, the first oral GLP-1 medication for weight loss, is now widely available across US pharmacies and telehealth providers, offering an effective option for adults with obesity or overweight with medical issues, with an average weight loss of about 17% if all patients stay on treatment.
Novo Nordisk's stock faced challenges in 2025 due to competition and demand issues, but the FDA approval of its Wegovy pill and plans to launch an oral version in 2026 present a strategic comeback opportunity, prompting investors to consider whether to buy, sell, or hold the stock.
The FDA has approved the first daily oral medication version of Wegovy, a popular weight-loss drug, giving Novo Nordisk an advantage over Eli Lilly, whose similar drug is still under review. The pill, containing semaglutide, has shown significant weight loss in clinical trials and is expected to be available soon, potentially expanding access and reducing costs for obesity treatments.
The FDA has approved a daily oral version of Wegovy, a GLP-1 weight-loss drug by Novo Nordisk, offering a new, more convenient option for obesity treatment alongside injectable forms and competitors like Lilly's orforglipron, with similar efficacy and side effects, and potential cost considerations.